Rapid growth in private testosterone prescribing raises safety concerns
The rapid expansion of private testosterone prescribing risks extending treatment beyond men with clearly defined need to people with non-specific symptoms and borderline test results, for whom the balance of benefit and long term risk are less certain, warn experts in The BMJ today.
Read original article on The Medical News →Related news
-
Ozempic and Wegovy linked to rare risk of sudden vision loss
United States
-
Parents of kids who need complex medical care at home tend to resolve frequent safety issues on their own, study finds
United Kingdom
-
Lasers and Doppler effect could personalize chemotherapy drug selection for cancer tumors
United Kingdom
-
AI detects daily stress by analyzing routine smartphone behaviors
United Kingdom
-
Global study exposes gaps in global endometriosis care guidelines
United Kingdom
-
Coffee drinkers had fewer repeat blood clots in a Norwegian study
United Kingdom
-
Experts call for lifelong care after brain and spinal injuries
United Kingdom
-
Bulk adverse event reporting may delay medical device safety warnings
United Kingdom